LFG
PACB icon

Larson Financial Group’s Pacific Biosciences PACB Stock Holding History

Larson Financial Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840 Buy
+500
New +$727 ﹤0.01% 3375

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Larson Financial Group's PACB Position: Q2 2026 in Review

Larson Financial Group opened a new position in Pacific Biosciences (PACB) in Q2 2026: 500 shares worth $840. The stake represents ﹤0.01% of the portfolio and ranks #3375 among its holdings.

223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Larson Financial Group held 500 shares of Pacific Biosciences worth $840 as of Q2 2026.
  • Pacific Biosciences was a new Larson Financial Group position in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3375 holding.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.